Cancer Biomarkers: The Urokinase Plasminogen Activator System

Molecular Mechanisms and Clinical Relevance
1. Auflage 2021
ISBN: 978-3-11-028339-6
Verlag: De Gruyter

Buch, Englisch, 450 Seiten, Format (B × H): 170 mm x 240 mm

The serine protease urokinase-type plasminogen activator, its inhibitor and its receptor are considered the most valuable prognostic cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. They are also among the few biomarkers that have been evaluated successfully in clinical studies for their clinical utility, for the most part in early breast cancer. This work provides an overview of the molecular mechanisms and clinical outlook of this important proteolytic system.

Autoren/Hrsg.

Schmitt, Manfred

Foekens, John

Sweep, Fred C.G.J.

Harbeck, Nadia

Brünner, Nils

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie

Über Autor(innen)

John A. Foekens, Erasmus Medical Center, Rotterdam, Netherlands; Fred Sweep, Radboud University Nijmegen, Netherlands; Nadia Harbeck, Ludwig-Maximilians-University, Munich, Germany; Nils Brünner, University Kopenhagen, Denmark; Manfred Schmitt,Technical University Munich, Germany.